EUGENE P. CAMPBELL, M.D.
During the past decade we have witnessed important changes in the therapeutic regimen of meningococcal meningitis. The traditional method of administering serum intrathecally has been generally discontinued in favor of the intravenous route. New and improved methods of making serum have resulted in the introduction of highly concentrated antiserum and antitoxin. Supporters of serum and antitoxin using new methods of administration of these biological preparations have claimed promising results. It almost goes without saying, however, that the general fatality from this disease has remained high in spite of these innovations. It is for the purpose of critical analysis of a
CAMPBELL EP. MENINGOCOCCAL MENINGITIS: REPORT OF FIFTY CASES, FORTY TREATED WITH SERUM AND TEN TREATED WITH SERUM AND SULFANILAMIDE(REPORT OF FIFTY CASES, FORTY TREATED WITH SERUM AND TEN TREATED WITH SERUM AND SULFANILAMIDE*). Ann Intern Med. 1942;16:694–700. doi: 10.7326/0003-4819-16-4-694
Download citation file:
Published: Ann Intern Med. 1942;16(4):694-700.
CNS Infections, Infectious Disease, Neurology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use